Gonadotropin-releasing hormone modulator
| Gonadotropin-releasing hormone modulator | |
|---|---|
| Drug class | |
 | |
| Class identifiers | |
| Synonyms | GnRH receptor modulator; GnRH analogue; GnRH agonist; GnRH antagonist |
| Use | Infertility; Prostate cancer; Precocious puberty; Breast cancer; Endometriosis; Uterine fibroids; Transgender people |
| Biological target | GnRH receptor |
| Chemical class | Peptide; Small-molecule (non-peptide) |
| In Wikidata | |
A GnRH modulator, or GnRH receptor modulator, is a type of medication which modulates the GnRH receptor, the biological target of the hypothalamic hormone gonadotropin-releasing hormone (GnRH).[1][2] They include GnRH agonists and GnRH antagonists. These medications may be GnRH analogues like leuprorelin and cetrorelix – peptides that are structurally related to GnRH – or small-molecules like elagolix, which are structurally distinct from GnRH analogues.
GnRH modulators affect the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn affects the gonads, influencing their function and hence fertility as well as the production of sex steroids, including that of estradiol and progesterone in women and of testosterone in men. As such, GnRH modulators can also be described as progonadotropic or antigonadotropic, depending on whether they act to increase or decrease gonadotropins.
GnRH agonists
Peptides
GnRH antagonists
Peptides
Non-peptides
a = Under development; not yet marketed.
See also
References
- ↑ Riggs MM, Bennetts M, van der Graaf PH, Martin SW (2012). "Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis". CPT Pharmacometrics Syst Pharmacol. 1: e11. doi:10.1038/psp.2012.10. PMC 3606940. PMID 23887363.
- ↑ Catherine Racowsky; Peter N. Schlegel; Bart C.J.M. Fauser; Douglas Carrell (7 June 2011). Biennial Review of Infertility. Springer Science & Business Media. pp. 80–. ISBN 978-1-4419-8456-2.